What You Need to Know About Krystal Biotech, Inc.'s Q3 Earnings
Krystal Biotech, Inc.'s fiscal Q3 earnings report was released on Monday, August 03. Let's dive in to see if (KRYS) missed or beat analyst's expectations.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Commentary & Analysis
Why Krystal Biotech, Inc.’s (KRYS) Stock Is Down 12.17%
As of Monday, August 03, Krystal Biotech, Inc.’s KRYS share price has dipped by 12.17%, which has investors questioning if this is right time to buy.Omar Beirat
Why Krystal Biotech, Inc.’s (KRYS) Stock Is Down 6.34%
As of Monday, August 03, Krystal Biotech, Inc.’s KRYS share price has dipped by 6.34%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Krystal Biotech, Inc.’s (KRYS) Stock Is Down 6.06%
As of Friday, July 31, Krystal Biotech, Inc.’s KRYS share price has dipped by 6.06%, which has investors questioning if this is right time to buy.Michael Rose
Is Krystal Biotech, Inc. (KRYS) Overvalued?
We dive into why Krystal Biotech, Inc. (KRYS) could be considered overvalued on 2026-07-23, based on AAII’s Value Score and Grade.Jenna Brashear
Financial Summary
| Share Statistics | KRYS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10,258.4 | $292.6 | 78% |
|
| Shares Out (Mil) | 30.7 | 54.4 | 37% |
|
| Institutional Ownership | 90.0% | 93.2% | 58% |
|
| Float (Mil) | 23.6 | 40.2 | 31% |
|
| Beta | 0.54 | 0.94 | 31% |
|
| Avg Daily Volume (000s) | 194 | 544 | 43% |
|
| Price Change (52-week) |
137.6% | 59.7% | 94% |
|
| Growth | KRYS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 52.9% | (10.1%) | 94% |
|
| EPS (5yr) | 43.1% | 16.0% | 90 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 4.0% | (15.6%) | 67% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 11 | 11 | |
| Current EPS | $1.996 | $7.865 | $9.398 | |
| Month Ago EPS | $2.206 | $8.308 | $9.865 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | $2.188 | $8.376 | $10.080 | |
| Year/Year Chg | 11.5% | 15.0% | 106.8% | |
| Financials | KRYS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $441 | $37 | 40% |
|
| Net Income (TTM) (Mil) | $242 | ($43) | 70% |
|
| EPS (TTM) | $8.265 | ($1.400) | 92% |
|
| Operating Cash Flow (TTM) (Mil) | $272 | ($31) | 63% |
|
| Net Cash Flow (TTM) (Mil) | $74 | $2 | 74% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $4 | 26% |
|
| Enterprise Value (Q1) (Mil) | $8,158 | $164 | 70% |
|
| Valuation | KRYS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.55 | 2.83 | 86% |
|
| P/E | 43.5 | 19.6 | 81% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 1.0 | 1.0 | 45% |
|
| Ratios | KRYS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 94.6% | 64.2% | 95% |
|
| Net Margin | 54.8% | (75.9%) | 97% |
|
| ROA | 18.3% | (47.5%) | 95% |
|
| ROE | 20.1% | (55.0%) | 79% |
|
| Liabilities to Assets | 9.4% | 29.6% | 5% |
|
| F-Score | 6 | 3 | 67% |
|
Krystal Biotech, Inc. did not pass any screens on 8/21/2026.
